1. Clinical & Scientific Overview
Thalidomide (TIP-MED-000543, Reference Code [R-24]) is classified under
Immunomodulators, Multiple Myeloma & ENL Therapy as a Cereblon E3 Ubiquitin Ligase Modulator (IMiD) & Anti-Angiogenic Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 + Mandatory Pregnancy Prevention Programme (High-Alert Teratogen).
Thalix (Fresenius Kabi Oncology / Dabur), Thaloda (Alkem Laboratories), Thalomid Reference
Hard Gelatin Capsule: 50 mg, 100 mg
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 + Mandatory Pregnancy Prevention Programme (High-Alert Teratogen)
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: EXTREME HUMAN TERATOGEN (Phocomelia / fatal embryopathy from a single capsule taken during organogenesis): Strictly contraindicated in pregnancy and women of childbearing potential unless two reliable contraceptive methods and negative pregnancy tests are documented; high risk of deep vein thrombosis/pulmonary embolism (requires thromboprophylaxis in myeloma) and irreversible axonal peripheral neuropathy.
Mandatory Dispensing Register & Institutional Custody Protocol: Dispense maximum 28-day supply only after verifying signed Pregnancy Prevention Consent, negative beta-hCG test, and barrier contraception instruction for both female and male patients (present in semen).
3. Mechanism of Action & Pharmacodynamics
Binds cereblon (CRBN), redirecting the CRL4-CRBN E3 ubiquitin ligase to ubiquitylate and degrade lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), while suppressing TNF-alpha, IL-6, and VEGF-mediated angiogenesis.
4. Therapeutic Indications & Evidence-Supported Uses
- Newly diagnosed multiple myeloma (in combination with dexamethasone and bortezomib)
- Moderate-to-severe Erythema Nodosum Leprosum (ENL / Type 2 lepra reaction)
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Thalidomide must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Hard Gelatin Capsule: 50 mg, 100 mg).
Administration & Meal Timing: Routes: Oral (at bedtime, at least 1 hour after evening meal). Dispense maximum 28-day supply only after verifying signed Pregnancy Prevention Consent, negative beta-hCG test, and barrier contraception instruction for both female and male patients (present in semen).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits cereblon e3 ubiquitin ligase modulator (imid) & anti-angiogenic agent pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Thalidomide or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: EXTREME HUMAN TERATOGEN (Phocomelia / fatal embryopathy from a single capsule taken during organogenesis): Strictly contraindicated in pregnancy and women of childbearing potential unless two reliable contraceptive methods and negative pregnancy tests are documented; high risk of deep vein thrombosis/pulmonary embolism (requires thromboprophylaxis in myeloma) and irreversible axonal peripheral neuropathy.
8. Adverse Effects Profile
- EXTREME HUMAN TERATOGEN (Phocomelia / fatal embryopathy from a single capsule taken during organogenesis): Strictly contraindicated in pregnancy and women of childbearing potential unless two reliable contraceptive methods and negative pregnancy tests are documented; high risk of deep vein thrombosis/pulmonary embolism (requires thromboprophylaxis in myeloma) and irreversible axonal peripheral neuropathy.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- EXTREME HUMAN TERATOGEN (Phocomelia / fatal embryopathy from a single capsule taken during organogenesis): Strictly contraindicated in pregnancy and women of childbearing potential unless two reliable contraceptive methods and negative pregnancy tests are documented; high risk of deep vein thrombosis/pulmonary embolism (requires thromboprophylaxis in myeloma) and irreversible axonal peripheral neuropathy.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- EXTREME HUMAN TERATOGEN (Phocomelia / fatal embryopathy from a single capsule taken during organogenesis): Strictly contraindicated in pregnancy and women of childbearing potential unless two reliable contraceptive methods and negative pregnancy tests are documented; high risk of deep vein thrombosis/pulmonary embolism (requires thromboprophylaxis in myeloma) and irreversible axonal peripheral neuropathy.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Dispense maximum 28-day supply only after verifying signed Pregnancy Prevention Consent, negative beta-hCG test, and barrier contraception instruction for both female and male patients (present in semen).
Pharmacist Patient Counselling Points:
- Dispense maximum 28-day supply only after verifying signed Pregnancy Prevention Consent, negative beta-hCG test, and barrier contraception instruction for both female and male patients (present in semen).
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Dispense maximum 28-day supply only after verifying signed Pregnancy Prevention Consent, negative beta-hCG test, and barrier contraception instruction for both female and male patients (present in semen).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.